Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
No open-market purchase by an insider of Steris is on record in SEC filings since 2006.
How often do Steris insiders buy and sell shares?
Since 2019, Steris insiders reported 0 open-market purchases and 187 sales on Forms 4 and 5.
Who is selling Steris stock?
In the last 90 days, 3 insiders of Steris (STE) reported 4 open-market sales worth $3.27M in total on SEC Form 4. The largest seller by value was Karen L Burton, with $1.5M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade STE?
Yes. Members of Congress disclosed 16 trades in Steris (STE) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Kevin Hern (OK01), Rep. April McClain Delaney (MD06), Rep. Jared Moskowitz (FL23) and 1 other member.
When does Steris report its next results?
Steris's next results are expected on Feb 2, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−0.5% (−$1.22) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $256.98 on Nov 20, 2025 to $255.76 on Nov 20, 2026 (−0.5%). Disclosed in this range: 12 insider trades, 0 pre-arranged insider sales, 16 Congress trades, and 58 13F position changes for 3 quarters ending in it.
$180$200$220$240$280$255.76
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 28 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in Dublin, Ireland.
Last 12 months
−0.5%
S&P 500 +5.7% over the same dates
Market value
$24.8B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.18M shares sold short (2.2% of shares outstanding), −9.0% vs the previous count, 2.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$1.59B
+8.8% vs the same quarter a year earlier
Free cash flow, last 12 months
$937M
This quarter $213M, a year earlier $201M
Net debt
$1.12B
Debt $1.65B, cash $531M, at Sep 30, 2026
Backlog
$1.53B
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Insiders of Steris reported 0 open-market purchases and 187 sales since 2019; no open-market purchase.
Year
Bought
Sold
2026
—
$6.52M10×10 trades
2025
—
$19.1M18×18 trades
2024
—
$24.9M22×22 trades
2023
—
$5.19M7×7 trades
2022
—
$7.69M8×8 trades
2021
—
$17.1M13×13 trades
2020
—
$62.8M58×58 trades
2019
—
$116M51×51 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
When insiders usually buy
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 2, 2027
Purchases after results
Not enough history
From Steris's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Steris's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Since Nov 19, 2025, STE is up 0.4% and the index fund is up 4.1%: 4 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much STE moves
A usual day
±1.0%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
2.5%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−7.7%Feb 5, 2026
Largest one-day rise
+7.2%Nov 4, 2026
Deepest fall of the year
−25.8%From the close of Jan 16, 2026 to Jun 17, 2026.
Days of 5% or more
3Out of 252 sessions, in either direction.
Beta 0.4(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Last 30 days
Written by software from the filings listed below · Nov 22, 2026
Insiders. In the 30 days to Nov 22, 2026, insiders of Steris filed 0 open-market purchases and 4 open-market sales (about $3.27M, in 3 filings, by 3 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales. (Steris on OQRO)
Congress. Members of Congress filed 0 disclosures on Steris in the 30 days to Nov 22, 2026: 0 purchases and 0 sales, by 0 members. In the 30 days before that: 1 disclosure.
Contracts, lobbying and filings. FDA records list 2 device clearances for Steris between Oct 23, 2026 and Nov 22, 2026; the latest, on Oct 29, 2026: device clearance for V-Pro maX 2 Low Temperature Sterilization System (510(k) clearance, special: Substantially Equivalent). FINRA short interest for STE on the settlement date of Oct 30, 2026 was 2,180,676 shares (-9.04% on the previous report), about 2.94 days of average volume.
Company reports, price and press. Steris filed a Form 8-K on Nov 4, 2026 (Items 2.02, 2.05) that OQRO classes as: announced job cuts, closures or a restructuring, and reported its results. The press release filed with it is titled: "STERIS Announces Financial Results for Fiscal 2027 Second Quarter"
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 22, 2026, insiders of Steris filed 0 open-market purchases and 4 open-market sales (about $3.27M, in 3 filings, by 3 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales.
The largest sale: Karen L Burton, Sr. Vice Pres., CFO, about $1.5M, filed Nov 12, 2026.
Congress
Members of Congress filed 0 disclosures on Steris in the 30 days to Nov 22, 2026: 0 purchases and 0 sales, by 0 members. In the 30 days before that: 1 disclosure.
Contracts, lobbying and filings
FDA records list 2 device clearances for Steris between Oct 23, 2026 and Nov 22, 2026; the latest, on Oct 29, 2026: device clearance for V-Pro maX 2 Low Temperature Sterilization System (510(k) clearance, special: Substantially Equivalent).
FINRA short interest for STE on the settlement date of Oct 30, 2026 was 2,180,676 shares (-9.04% on the previous report), about 2.94 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Orbis Allan Gray Ltd (increased, 84,798 shares); Worldquant Millennium Advisors LLC (new position); the largest that shrank: Conestoga Capital Advisors, LLC (sold out); TIAA Wealth Investment Management LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2026, the company's proxy statement reported total compensation of $11.5M for its principal executive officer, and an average of $2.58M for the other named executive officers.
Company reports, price and press
Steris filed a Form 8-K on Nov 4, 2026 (Items 2.02, 2.05) that OQRO classes as: announced job cuts, closures or a restructuring, and reported its results.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Steris filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 15 open-market sales (about $9.13M, in 10 filings, by 8 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 14 open-market sales (about $16.9M, in 10 filings). (Steris on OQRO)
Congress. Members of Congress filed 16 disclosures on Steris in the 12 months to Nov 19, 2026: 9 purchases and 7 sales, by 4 members. In the 12 months before that: 4 disclosures. The largest range: Rep. April McClain Delaney (MD06), $100,001 to $250,000, filed Sep 9, 2026.
Funds and stakes. Fund 13F filings recorded in the 12 months show 24 new or larger positions and 34 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. 9 lobbying reports naming the company were posted in the 12 months, reporting about $550K. FDA records list 6 device clearances, 14 recalls for Steris between Nov 19, 2025 and Nov 19, 2026; the latest, on Oct 29, 2026: device clearance for V-Pro maX 2 Low Temperature Sterilization System (510(k) clearance, special: Substantially Equivalent).
Company reports, price and press. Steris filed a Form 8-K on Nov 4, 2026 (Items 2.02, 2.05) that OQRO classes as: announced job cuts, closures or a restructuring, and reported its results. Steris filed a Form 8-K on Aug 6, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
Who holds it. 828 funds reported a stake in Steris in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (9.3% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (6.7% of the value reported), STATE STREET CORP (5.3% of the value reported).
Deals. Steris is the buyer of Xodus Medical, Inc., a deal of about $2.1B; status: pending, first on record Oct 13, 2026.
Attention. The English Wikipedia article on Steris was read about 32 times a day in the 7 days to Nov 18, 2026, against a usual 40 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Steris filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 15 open-market sales (about $9.13M, in 10 filings, by 8 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 14 open-market sales (about $16.9M, in 10 filings).
The largest sale: Karen L Burton, Sr. Vice Pres., CFO, about $1.5M, filed Nov 12, 2026.
Congress
Members of Congress filed 16 disclosures on Steris in the 12 months to Nov 19, 2026: 9 purchases and 7 sales, by 4 members. In the 12 months before that: 4 disclosures.
The largest range: Rep. April McClain Delaney (MD06), $100,001 to $250,000, filed Sep 9, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 24 new or larger positions and 34 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
9 lobbying reports naming the company were posted in the 12 months, reporting about $550K.
FDA records list 6 device clearances, 14 recalls for Steris between Nov 19, 2025 and Nov 19, 2026; the latest, on Oct 29, 2026: device clearance for V-Pro maX 2 Low Temperature Sterilization System (510(k) clearance, special: Substantially Equivalent).
FINRA short interest for STE on the settlement date of Oct 30, 2026 was 2,180,676 shares (-9.04% on the previous report), about 2.94 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Orbis Allan Gray Ltd (increased, 84,798 shares); Worldquant Millennium Advisors LLC (new position); the largest that shrank: Conestoga Capital Advisors, LLC (sold out); TIAA Wealth Investment Management LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
The press release filed with it is titled: "STERIS Announces Financial Results for Fiscal 2027 Second Quarter"
Its announcing sentence reads: "STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2027 second quarter ended September 30, 2026."
Steris filed a Form 8-K on Nov 4, 2026 (Items 1.01, 1.02, 2.03) that OQRO classes as: signed an important agreement, and ended an important agreement (and 1 more item).
Press coverage listed by Finnhub: "If You Invested $1000 In Steris Stock 10 Years Ago, You Would Have This Much Today" (Benzinga, Nov 16, 2026).
Press coverage listed by Finnhub: "STERIS plc Q2 2027 Earnings Call Summary" (Yahoo, Nov 5, 2026).
Press coverage listed by Finnhub: "STE Stock Up on Q2 Earnings & Revenue Beat, '27 EPS View Up" (Yahoo, Nov 5, 2026).
STE closed at $255.76 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $221.48 to $255.76, a change of +15.5%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
For fiscal 2026, the company's proxy statement reported total compensation of $11.5M for its principal executive officer, and an average of $2.58M for the other named executive officers.
Company reports, price and press
Steris filed a Form 8-K on Nov 4, 2026 (Items 2.02, 2.05) that OQRO classes as: announced job cuts, closures or a restructuring, and reported its results.
Steris filed a Form 8-K on Aug 6, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On July 31, 2026, Pierre Boulud was appointed to serve on the Audit Committee of the Board and the Compliance and Technology Committee of the Board."
Steris filed a Form 8-K on Aug 5, 2026 (Items 2.02, 2.05) that OQRO classes as: announced job cuts, closures or a restructuring, and reported its results.
The company's own opening sentence of that report reads: "On August 5, 2026, the Company announced a targeted consolidation plan (the 'Consolidation Plan') to consolidate existing manufacturing and distribution for formulated chemistries to a new Center of Excellence in North Carolina."
Press coverage listed by Finnhub: "If You Invested $1000 In Steris Stock 10 Years Ago, You Would Have This Much Today" (Benzinga, Nov 16, 2026).
Press coverage listed by Finnhub: "STERIS plc Q2 2027 Earnings Call Summary" (Yahoo, Nov 5, 2026).
Press coverage listed by Finnhub: "STE Stock Up on Q2 Earnings & Revenue Beat, '27 EPS View Up" (Yahoo, Nov 5, 2026).
STE closed at $259.57 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $221.97 to $259.57, a change of +16.9%.
Who holds it
828 funds reported a stake in Steris in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (9.3% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (6.7% of the value reported), STATE STREET CORP (5.3% of the value reported).
Deals
Steris is the buyer of Xodus Medical, Inc., a deal of about $2.1B; status: pending, first on record Oct 13, 2026.
Attention
The English Wikipedia article on Steris was read about 32 times a day in the 7 days to Nov 18, 2026, against a usual 40 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Latest annual report filed May 29, 2026, compared with the one filed May 29, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
Our investments in our business and product offerings may not be as successful as anticipated.
No longer listed (3 headings from the year before)
We might be adversely impacted by tax legislation or challenges to our tax positions.
The U.S. Internal Revenue Service (the “IRS”) may not agree that we are a non-U.S. corporation for U.S. federal tax purposes.
We may fail to realize all of the anticipated benefits of our strategic business initiatives, as well as acquisitions, dispositions or joint ventures, or those benefits may take longer to realize than expected.
Legal proceedings (Item 3)
Information regarding our legal proceedings is included in Item 7 of Part II, Management's Discussion and Analysis, and Note 12 to our consolidated financial statements titled, "Commitments and Contingencies," and is incorporated herein by reference thereto.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed May 29, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Where the revenue comes from
Fiscal year Apr 1, 2025 to Mar 31, 2026, from the annual report filed May 29, 2026. Read the filing
By business segment
Healthcare Segment$4.21B71%
+8.5% on the year before ($3.88B)
AST$1.14B19%
+9.6% on the year before ($1.04B)
Life Sciences$589M9.9%
+8.6% on the year before ($542M)
Total revenue$5.94B+8.7%
By product or service
Product$3.06B52%
+6.6% on the year before ($2.87B)
Service$2.88B48%
+11% on the year before ($2.59B)
Total revenue$5.94B+8.7%
By region
United States$4.33B73%
+8.1% on the year before ($4.01B)
Other foreign locations$1.49B25%
+11% on the year before ($1.34B)
IRELAND$109M1.8%
+1.1% on the year before ($107M)
Total revenue$5.94B+8.7%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 13,000 words.
From “INTRODUCTION”, in the company's words
In Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), we explain the general financial condition and the results of operations for STERIS and its subsidiaries including: what factors affect our business; what our earnings and costs were in each period presented; why those earnings and costs were different from the year before; where our earnings came from; how this affects our overall financial condition; what our expenditures for capital projects were; and where cash is expected to come from to fund future debt principal repayments, growth outside of core operations, repurchases of shares, cash dividends and future working capital needs.
What the section covers (15 headings)
INTRODUCTION
FINANCIAL MEASURES
REVENUES– DEFINED
GENERAL OVERVIEW AND EXECUTIVE SUMMARY
NON-GAAP FINANCIAL MEASURES
RESULTS OF OPERATIONS
FISCAL 2026 AS COMPARED TO FISCAL 2025
Business Segment Results of Operations
LIQUIDITY AND CAPITAL RESOURCES
CAPITAL EXPENDITURES
MATERIAL FUTURE CASH OBLIGATIONS AND COMMERCIAL COMMITMENTS
SUPPLEMENTAL GUARANTOR FINANCIAL INFORMATION
Source: SEC EDGAR, Form 10-K filed May 29, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
People read Steris's Wikipedia article about 30 times a day over the last week, fewer than the 40 on a usual day of the three months before.
May 16, 2026Busiest day: 85 views on Oct 12, 2026Nov 21, 2026
Views of the article Steris, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
FDA, last 12 months
6 approvals or clearances and 13 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Short sale volume: 60.4% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 57.6%. FINRA daily files, to Nov 20, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Off-exchange trading: 44.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (29.5% on ATS, 15.4% with other brokers), close to its 26-week average of 43.0%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: UBS ATS (14.1%), SIGMA X2 (14.0%), INTELLIGENT CROSS LLC (9.5%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.